Evidence map›Paper›PMID 37971631›Full record

ArticleEndocrine2024

Renal safety of zoledronic acid in patients with osteoporosis: a retrospective study.

Yanhua Ma, Shen Xu, Zhongyue Xu, Ying Zhang, Chunyan Lu, Decai Chen, Qin Wang

Abstract read
PubMed Publisher
In one paragraph

Article in Endocrine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.7field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Yanhua MaDepartment of Endocrinology, West China Hospital of Sichuan University, Chengdu, China.
Shen XuDepartment of Endocrinology, West China Hospital of Sichuan University, Chengdu, China.
Zhongyue XuDepartment of Endocrinology, West China Hospital of Sichuan University, Chengdu, China.
Ying ZhangDepartment of Endocrinology, West China Hospital of Sichuan University, Chengdu, China.
Chunyan LuDepartment of Endocrinology, West China Hospital of Sichuan University, Chengdu, China.
Decai ChenDepartment of Endocrinology, West China Hospital of Sichuan University, Chengdu, China.
Qin WangDepartment of Endocrinology, West China Hospital of Sichuan University, Chengdu, China. wangqin@wchscu.cn.ORCID 0000-0003-1217-1387
Sichuan University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionThis study aimed to investigate the renal safety of Zoledronic Acid (ZOL) in patients with osteoporosis (OP).

methodsA total of 1379 patients (baseline estimated glomerular filtration rate, eGFR ≥ 60 mL/min/1.73 m

resultsRenal impairment occurred in 8.05% of patients, who with a significantly higher age, Charlson Comorbidity Index (CCI), smoking history, combination of hypertension or diabetes mellitus and worse renal function indicators (all P < 0.05). Binary logistic regression analysis showed that higher CCI (≥5) or smoking history or the baseline eGFR <90 mL/min/1.73 m

conclusionAttention should be given to possible potential renal impairment following ZOL infusion in clinical practice for the management of OP, particularly in patients with higher CCI (≥5) or smoking history or the baseline eGFR <90 mL/min/1.73 m

Indexed as

Bone Density Conservation AgentsOsteoporosisDiphosphonatesHumansImidazolesKidneyRetrospective StudiesZoledronic AcidBone Density Conservation AgentsDiphosphonatesImidazolesZoledronic AcidOsteoporosisRenal functionRetrospective studySafetyZoledronic acid

Identifiers

PMID37971631
OpenAlexW4388724650

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.